HTBX
Income statement / Annual
Last year (2021), Heat Biologics, Inc.'s total revenue was $2.11 M,
a decrease of 28.33% from the previous year.
In 2021, Heat Biologics, Inc.'s net income was -$35.40 M.
See Heat Biologics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$2.11 M |
$2.95 M |
$3.05 M |
$5.79 M |
$1.52 M |
$341.64 K |
$0.00 |
$0.00 |
$0.00 |
$3.11 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$2.11 M
|
$2.95 M
|
$3.05 M
|
$5.79 M
|
$1.52 M
|
$341.64 K
|
$0.00
|
$0.00
|
$0.00
|
$3.11 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
| Research and Development Expenses |
$18.82 M
|
$12.94 M
|
$13.01 M
|
$16.23 M
|
$8.27 M
|
$9.33 M
|
$2.60 M
|
$2.86 M
|
$2.74 M
|
$902.94 K
|
| General & Administrative Expenses |
$16.83 M
|
$15.00 M
|
$9.43 M
|
$7.03 M
|
$0.00
|
$4.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.83 M
|
$15.00 M
|
$9.43 M
|
$7.03 M
|
$0.00
|
$4.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Other Expenses |
$1.88 M
|
$0.00
|
$0.00
|
$0.00
|
$6.37 M
|
$0.00
|
$18.43 M
|
$9.33 M
|
$3.83 M
|
$1.44 M
|
| Operating Expenses |
$37.53 M
|
$27.94 M
|
$22.44 M
|
$23.26 M
|
$14.64 M
|
$13.47 M
|
$21.02 M
|
$12.19 M
|
$6.56 M
|
$2.35 M
|
| Cost And Expenses |
$37.53 M
|
$27.94 M
|
$22.44 M
|
$23.26 M
|
$14.64 M
|
$13.47 M
|
$21.02 M
|
$12.19 M
|
$6.56 M
|
$2.35 M
|
| Interest Income |
$815.32 K
|
$566.72 K
|
$431.82 K
|
$265.75 K
|
$22.17 K
|
$31.14 K
|
$66.00 K
|
$40.57 K
|
$10.07 K
|
$2.00
|
| Interest Expense |
$127.74 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$549.40 K
|
$364.00 K
|
$73.35 K
|
$79.12 K
|
$101.09 K
|
| Depreciation & Amortization |
-$127.74 K
|
$333.15 K
|
$232.51 K
|
$237.32 K
|
$134.08 K
|
$132.08 K
|
$116.00 K
|
$66.90 K
|
$6.35 K
|
$2.59 K
|
| EBITDA |
-$35.55 M |
-$25.72 M |
-$19.74 M |
-$16.48 M |
-$12.52 M |
-$11.89 M |
-$19.82 M |
-$11.65 M |
-$8.63 M |
-$2.32 M |
| EBITDA Ratio |
-16.82
|
-8.72
|
-6.47
|
-2.84
|
-8.24
|
-34.81
|
0
|
0
|
0
|
-744.86
|
| Operating Income Ratio |
-16.76
|
-8.86
|
-6.8
|
-3.1
|
-8.78
|
-38.42
|
0
|
0
|
0
|
-753.27
|
| Total Other Income/Expenses Net |
-$127.74 K
|
-$257.03 K
|
$406.27 K
|
$383.53 K
|
$123.44 K
|
$152.52 K
|
-$100.00 K
|
-$56.28 K
|
-$45.22 K
|
-$108.34 K
|
| Income Before Tax |
-$35.55 M
|
-$26.38 M
|
-$20.34 M
|
-$17.58 M
|
-$13.22 M
|
-$12.97 M
|
-$21.12 M
|
-$12.24 M
|
-$6.61 M
|
-$2.45 M
|
| Income Before Tax Ratio |
-16.82
|
-8.95
|
-6.67
|
-3.03
|
-8.7
|
-37.98
|
0
|
0
|
0
|
-788.11
|
| Income Tax Expense |
-$145.97 K
|
-$257.03 K
|
$45.18 K
|
-$985.49 K
|
-$809.54 K
|
$701.92 K
|
$264.00 K
|
$17.07 K
|
$33.90 K
|
-$7.26 K
|
| Net Income |
-$35.40 M
|
-$26.05 M
|
-$20.02 M
|
-$15.73 M
|
-$11.84 M
|
-$12.57 M
|
-$20.30 M
|
-$11.79 M
|
-$8.71 M
|
-$2.42 M
|
| Net Income Ratio |
-16.76
|
-8.84
|
-6.57
|
-2.72
|
-7.79
|
-36.8
|
0
|
0
|
0
|
-778.2
|
| EPS |
-1.41 |
-1.63 |
-4.21 |
-6.3 |
-21.56 |
-49.4 |
-174.92 |
-126.18 |
-160.61 |
-90.87 |
| EPS Diluted |
-1.41 |
-1.63 |
-4.21 |
-6.3 |
-21.56 |
-49.4 |
-174.92 |
-126.18 |
-160.61 |
-90.87 |
| Weighted Average Shares Out |
$25.14 M
|
$15.98 M
|
$4.75 M
|
$2.50 M
|
$549.33 K
|
$254.55 K
|
$116.02 K
|
$93.43 K
|
$54.24 K
|
$26.63 K
|
| Weighted Average Shares Out Diluted |
$25.14 M
|
$15.98 M
|
$4.75 M
|
$2.50 M
|
$549.33 K
|
$254.55 K
|
$116.02 K
|
$93.43 K
|
$54.24 K
|
$26.63 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
